黑色素瘤
癌症研究
医学
靶向治疗
免疫疗法
突变
MAPK/ERK通路
癌症
V600E型
免疫学
生物
激酶
基因
内科学
遗传学
作者
Giorgia Castellani,Mariachiara Buccarelli,Maria Beatrice Arasi,Stefania Rossi,Maria Elena Pisanu,Maria Bellenghi,Carla Lintas,Claudio Tabolacci
出处
期刊:Cancers
[Multidisciplinary Digital Publishing Institute]
日期:2023-08-08
卷期号:15 (16): 4026-4026
被引量:235
标识
DOI:10.3390/cancers15164026
摘要
Melanoma is an aggressive form of skin cancer resulting from the malignant transformation of melanocytes. Recent therapeutic approaches, including targeted therapy and immunotherapy, have improved the prognosis and outcome of melanoma patients. BRAF is one of the most frequently mutated oncogenes recognised in melanoma. The most frequent oncogenic BRAF mutations consist of a single point mutation at codon 600 (mostly V600E) that leads to constitutive activation of the BRAF/MEK/ERK (MAPK) signalling pathway. Therefore, mutated BRAF has become a useful target for molecular therapy and the use of BRAF kinase inhibitors has shown promising results. However, several resistance mechanisms invariably develop leading to therapeutic failure. The aim of this manuscript is to review the role of BRAF mutational status in the pathogenesis of melanoma and its impact on differentiation and inflammation. Moreover, this review focuses on the mechanisms responsible for resistance to targeted therapies in BRAF-mutated melanoma and provides an overview of circulating biomarkers including circulating tumour cells, circulating tumour DNA, and non-coding RNAs.
科研通智能强力驱动
Strongly Powered by AbleSci AI